Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor BiopsiesJeffrey Houghton 1, Andrew G. Hadd 1, Robert Zeigler 1, Brian C. Haynes 1, Gary J. Latham 1
1Asuragen, Inc.
An integrated system for targeted next-generation sequencing of oncology specimens is described. This cross-platform system is optimized for low-quality and low-quantity tumor biopsies, accommodates low DNA inputs, includes well-characterized multi-variant controls, and features a novel variant caller that is informed by quantitative pre-analytical quality control measures.
